Composition Wealth LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.0% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,868 shares of the company’s stock after buying an additional 909 shares during the period. Composition Wealth LLC’s holdings in Eli Lilly and Company were worth $27,617,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in LLY. Coastal Bridge Advisors LLC bought a new position in Eli Lilly and Company in the second quarter valued at $2,959,000. Birinyi Associates Inc. lifted its stake in Eli Lilly and Company by 32.6% during the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after purchasing an additional 359 shares during the last quarter. Bernicke Wealth Management Ltd. bought a new stake in Eli Lilly and Company during the third quarter worth about $5,001,000. Mosaic Family Wealth Partners LLC lifted its stake in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Finally, Trillium Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 1,302.8% in the 3rd quarter. Trillium Asset Management LLC now owns 5,036 shares of the company’s stock worth $5,831,000 after purchasing an additional 4,677 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. Leerink Partners boosted their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. Truist Financial restated a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price for the company in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,422.00.
Check Out Our Latest Analysis on Eli Lilly and Company
Insider Buying and Selling at Eli Lilly and Company
In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
Eli Lilly and Company Price Performance
Shares of NYSE:LLY opened at $1,412.63 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.33 trillion, a PE ratio of 45.85, a PEG ratio of 1.71 and a beta of 0.40. The company’s fifty day moving average is $1,253.71 and its 200 day moving average is $1,114.28. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,475.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the business posted $7.02 earnings per share. The company’s revenue was up 38.6% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.
Key Eli Lilly and Company News
Investors following LLY have been watching these news items:
- Positive Sentiment: Lilly signed a cancer-research and licensing agreement with Stipple Bio worth up to $5.9 billion, using Stipple’s platform to pursue targeted therapies for solid tumors. Stipple expects to begin a Phase 1 trial in early 2027; the deal diversifies Lilly’s pipeline, though the potential value depends on development milestones. Article: Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
- Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and $1,600 price target, implying analyst confidence in further upside. Royal Bank of Canada recommendations
- Neutral Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to add experimental treatments for rare blood cancers. The acquisition broadens its oncology pipeline, but clinical and regulatory milestones will determine the ultimate value and cost. Article: Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
